Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
about
Hormone therapy for preventing cardiovascular disease in post-menopausal womenHormone therapy for preventing cardiovascular disease in post-menopausal womenPatient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifeneThe evolution of selective estrogen receptor modulators in osteoporosis therapyNew antiresorptive therapies for postmenopausal osteoporosisEffects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in miceBreast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexesTissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.Occult breast tumor reservoir: biological properties and clinical significance.Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model.Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.Conjugated Estrogens/Bazedoxifene (Duavee): A Novel Agent for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause And the Prevention of Postmenopausal Osteoporosis.Treatment of the genitourinary syndrome of menopause.Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy.Effects of Combination of Estradiol with Selective Progesterone Receptor Modulators (SPRMs) on Human Breast Cancer Cells In Vitro and In Vivo.Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosisProgestogen safety and tolerance in hormonal replacement therapy.Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause.Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis in postmenopausal monkeys.Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes.The Tissue-Selective Estrogen Complex: A Review of Current EvidenceProfile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fractureManagement of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combinationEffects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeysThe tissue selective estrogen complex: a promising new menopausal therapyEndometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate modelEndometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment.Conjugated estrogens and bazedoxifeneBazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE).Evolution of the tissue selective estrogen complex (TSEC).Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis.Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health.Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.Advances in menopausal therapy: the tissue-selective estrogen complex.Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.
P2860
Q24187326-65E79E41-975B-42BD-AF99-BD7ABB7124DEQ24197712-7480DEA0-1D58-4073-B35B-D2EE8E9A23A9Q26751149-D8F2D414-673A-4353-89BC-2E5F928977C9Q26827973-6019CE26-5F60-4BB1-8887-C6A062FC53ABQ27014775-067B8C71-E7F7-4216-B6BB-0FD7D81A70D0Q30353161-B92B92FD-06CD-4717-A21B-8B1F06BC9CE6Q30409045-7B77A5A3-5247-4802-901F-463ED8437074Q30454254-B3E92DED-124A-40B7-879A-8A9EE2FD0F27Q30455905-1D9CD528-2C0D-4DC5-8AC4-2BB016B0CBCFQ30456637-350ADBEC-0AA4-4CD4-AB86-3892C7A8D3DDQ30456770-5E1DAAC4-389C-4A6C-9BC8-122B76B132F4Q33888331-133CB1DA-EB0D-4800-89A0-77B862E4643EQ34490225-229614FE-AE1D-4DC5-A76C-83E3A07C3B5DQ35170566-2D03F071-D7B8-4CB0-BA53-F09304F1005AQ35772318-F6242D96-4D0C-4D47-9D5E-C6ABE8CEB1DDQ35885187-0845F49A-0FC8-4F3E-8469-43C9930025DEQ35969254-5896D948-6031-47D9-9E95-2EDB4AE33B75Q36059535-31AB510F-FB23-4AF0-9FC8-80F9ABE3EA2BQ36109111-782E376D-9F6C-4EDB-A353-0F4A0F532501Q36301767-E4522976-7F22-412E-B653-1EDEF1CAFE11Q36626118-231BDAB0-A85A-459A-8B7B-8E297338645CQ36776727-C814C691-F765-4CAC-ABF8-0571AAD99293Q36942968-7F9CBB7F-B486-4BE6-8D28-A6B20AFE6793Q37048294-CB7CA943-DEE2-4FA9-8B96-7F2737AFE74BQ37095740-CFA00542-BA27-4723-A09D-62FF1B127916Q37146858-B1C02A19-E8F3-409A-9170-2E9B726EC831Q37277298-361728C7-A66C-4A94-985B-0C06C7616DA0Q37483322-29740325-A905-4D47-AAB3-D3C459EBC574Q37648048-22CB1B6F-E88F-4F9D-A339-063AC1E7E090Q37676345-12F464D7-3CD2-4DFC-8BC0-AFE0B2D92614Q37698607-70F25B5D-0D5B-4D30-B360-85AF79826FB0Q37808639-06C82BAA-5E20-4520-B232-10A5E2FBD20DQ38077503-FE738DAD-9880-4FEB-9B56-E53DA9CDCAA1Q38102040-BF1FF7B2-5454-4C96-A9EA-E92408A23A99Q38106748-A9B47457-F5CC-4D61-A3BD-A2A7875CC1C4Q38149162-8B045440-47B8-4410-BC87-9E5C9AF85E90Q38161857-C93F8EB2-EE11-46C4-9495-202F5D49462AQ38192058-3E20AFD4-A54F-4039-8C9E-7F10327C6A51Q38193873-46364C73-0FB6-4CC9-8C19-365395122ADBQ38230047-4B10619F-32F9-4316-804F-485EDD00BCDA
P2860
Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Relief of vasomotor symptoms w ...... randomized, controlled trial.
@ast
Relief of vasomotor symptoms w ...... randomized, controlled trial.
@en
type
label
Relief of vasomotor symptoms w ...... randomized, controlled trial.
@ast
Relief of vasomotor symptoms w ...... randomized, controlled trial.
@en
prefLabel
Relief of vasomotor symptoms w ...... randomized, controlled trial.
@ast
Relief of vasomotor symptoms w ...... randomized, controlled trial.
@en
P2093
P1433
P1476
Relief of vasomotor symptoms w ...... randomized, controlled trial.
@en
P2093
Ginger D Constantine
James H Pickar
JoAnn V Pinkerton
Sophie Olivier
Wulf H Utian
P304
P356
10.1097/GME.0B013E3181A7DF0D
P407
P577
2009-11-01T00:00:00Z